← Leaderboards
Adegboyega Oyelere
Georgia Institute Of Technology
$5,282,404
Attributed
$6,379,740
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,379,740 · 4
By mechanism
R01$6,020,406 · 3
R21$359,334 · 1
Top collaborators
- Chendil Damodaran4 shared
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadCellsHistone DeacetylaseTumorHistonesIn VitroDrug KineticsCancer EtiologyInsightPropertyIn VivoDesignReceptor ExpressionDrug ResistanceResistanceMalignant Neoplasm Of LungCytotoxicityMalignant NeoplasmsCessation Of LifeEpigenetic ProcessApoptosisCancer Cell GrowthAntineoplastic AgentsCancer Therapy
Grant awards (17)
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$549,548
R01 · FY2025 · CA · contact PI
Reposition and Optimization of Deferiprone for Breast Cancer Therapy$399,479
R01 · FY2025 · CA · contact PI
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$535,890
R01 · FY2024 · CA · contact PI
Reposition and Optimization of Deferiprone for Breast Cancer Therapy$449,889
R01 · FY2024 · CA · contact PI
Reposition and Optimization of Deferiprone for Breast Cancer Therapy$45,616
R01 · FY2024 · CA · contact PI
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$539,006
R01 · FY2023 · CA · contact PI
Reposition and Optimization of Deferiprone for Breast Cancer Therapy$532,229
R01 · FY2023 · CA · contact PI
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$570,229
R01 · FY2022 · CA · contact PI
Reposition and Optimization of Deferiprone for Breast Cancer Therapy$436,894
R01 · FY2022 · CA · contact PI
Reposition and Optimization of Deferiprone for Breast Cancer Therapy$505,386
R01 · FY2021 · CA · contact PI
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activit$196,621
R21 · FY2015 · CA · contact PI
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activit$162,713
R21 · FY2014 · CA · contact PI
Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung ca$274,783
R01 · FY2013 · CA · contact PI
Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung ca$292,322
R01 · FY2012 · CA · contact PI
Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung ca$292,321
R01 · FY2011 · CA · contact PI
Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung ca$301,362
R01 · FY2010 · CA · contact PI
Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung ca$295,452
R01 · FY2009 · CA · contact PI